Literature DB >> 15924149

Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells.

Kwang M Lee1, Hiroaki Yasuda, Michael A Hollingsworth, Michel M Ouellette.   

Abstract

Pancreatic adenocarcinomas display foci of duct-like structures that are positive for markers of pancreatic ductal cells. The development of these tumors is promoted by conditions leading to acinar-to-ductal metaplasia, a process by which acinar cells are replaced by ductal cells. Acinar-to-ductal metaplasia has recently been shown to proceed through intermediary cells expressing Nestin. To create an in vitro system to study pancreatic adenocarcinomas, we had used an hTERT cDNA to immortalize primary cells of the human pancreas. In this report, we show that the immortalized cells, termed hTERT-HPNE cells, have the ability to differentiate to pancreatic ductal cells. Exposing hTERT-HPNE cells to sodium butyrate and 5-aza-2'-deoxycytidine lead to the formation of pancreatic ductal cells marked by the expression of MDR-1, carbonic anhydrase II, and the cytokeratins 7, 8, and 19. hTERT-HPNE cells were found to have properties of the intermediary cells formed during acinar-to-ductal metaplasia, which included their undifferentiated phenotype, expression of Nestin, evidence of active Notch signaling, and ability to differentiate to pancreatic ductal cells. These results provide further evidence for the presence in the adult pancreas of a precursor of ductal cells. hTERT-HPNE cells should provide a useful model to study acinar-to-ductal metaplasia and the role played by this process in pancreatic cancer development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15924149     DOI: 10.1038/labinvest.3700298

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  46 in total

1.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Authors:  Jianhua Ling; Ya'an Kang; Ruiying Zhao; Qianghua Xia; Dung-Fang Lee; Zhe Chang; Jin Li; Bailu Peng; Jason B Fleming; Huamin Wang; Jinsong Liu; Ihor R Lemischka; Mien-Chie Hung; Paul J Chiao
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

2.  Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.

Authors:  Victoria H Cruz; Emily N Arner; Wenting Du; Alberto E Bremauntz; Rolf A Brekken
Journal:  JCI Insight       Date:  2019-04-02

3.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

4.  Imbalanced expression of Tif1γ inhibits pancreatic ductal epithelial cell growth.

Authors:  Martin Ligr; Xinyu Wu; Garrett Daniels; David Zhang; Huamin Wang; Cristina Hajdu; Jinhua Wang; Ruimin Pan; Zhiheng Pei; Lanjing Zhang; Marcovalerio Melis; Matthew R Pincus; John K Saunders; Peng Lee; Ruliang Xu
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

5.  Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras.

Authors:  John P Eggers; Paul M Grandgenett; Eric C Collisson; Michelle E Lewallen; Jarrod Tremayne; Pankaj K Singh; Benjamin J Swanson; Judy M Andersen; Thomas C Caffrey; Robin R High; Michel Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2011-08-08       Impact factor: 12.531

6.  Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity.

Authors:  Yongji Zeng; Seth Stauffer; Jiuli Zhou; Xingcheng Chen; Yuanhong Chen; Jixin Dong
Journal:  J Biol Chem       Date:  2017-07-24       Impact factor: 5.157

7.  Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma.

Authors:  Pawel K Mazur; Henrik Einwächter; Marcel Lee; Bence Sipos; Hassan Nakhai; Roland Rad; Ursula Zimber-Strobl; Lothar J Strobl; Freddy Radtke; Günter Klöppel; Roland M Schmid; Jens T Siveke
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

8.  Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.

Authors:  Georg Feldmann; Anjali Mishra; Seung-Mo Hong; Savita Bisht; Christopher J Strock; Douglas W Ball; Michael Goggins; Anirban Maitra; Barry D Nelkin
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

9.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

10.  Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.

Authors:  Shao-Jie Chen; Yin-Ting Chen; Lin-Juan Zeng; Qiu-Bo Zhang; Guo-da Lian; Jia-Jia Li; Ke-Ge Yang; Chu-Mei Huang; Ya-Qing Li; Zhong-Hua Chu; Kai-Hong Huang
Journal:  Tumour Biol       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.